Studies have found that patients with high co-expression of MAGE-A4 and MHC class I molecules in tumor cells are more likely to develop MAGE-A4-specific immune responses after MAGE-A4 vaccination and have longer overall survival. This evidence concerns the gene MAGEA4 and neoplasm.